1. Home
  2. LGND vs KYN Comparison

LGND vs KYN Comparison

Compare LGND & KYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LGND
  • KYN
  • Stock Information
  • Founded
  • LGND 1987
  • KYN 2004
  • Country
  • LGND United States
  • KYN United States
  • Employees
  • LGND N/A
  • KYN N/A
  • Industry
  • LGND Biotechnology: Pharmaceutical Preparations
  • KYN Finance/Investors Services
  • Sector
  • LGND Health Care
  • KYN Finance
  • Exchange
  • LGND Nasdaq
  • KYN Nasdaq
  • Market Cap
  • LGND 2.3B
  • KYN 2.2B
  • IPO Year
  • LGND 1992
  • KYN N/A
  • Fundamental
  • Price
  • LGND $111.89
  • KYN $13.15
  • Analyst Decision
  • LGND Strong Buy
  • KYN
  • Analyst Count
  • LGND 6
  • KYN 0
  • Target Price
  • LGND $145.00
  • KYN N/A
  • AVG Volume (30 Days)
  • LGND 124.3K
  • KYN 561.5K
  • Earning Date
  • LGND 02-25-2025
  • KYN 01-01-0001
  • Dividend Yield
  • LGND N/A
  • KYN 8.99%
  • EPS Growth
  • LGND 160.46
  • KYN N/A
  • EPS
  • LGND 2.47
  • KYN 0.71
  • Revenue
  • LGND $152,422,000.00
  • KYN N/A
  • Revenue This Year
  • LGND $26.86
  • KYN N/A
  • Revenue Next Year
  • LGND $14.95
  • KYN N/A
  • P/E Ratio
  • LGND $45.27
  • KYN $13.79
  • Revenue Growth
  • LGND N/A
  • KYN N/A
  • 52 Week Low
  • LGND $67.72
  • KYN $7.84
  • 52 Week High
  • LGND $129.90
  • KYN $9.88
  • Technical
  • Relative Strength Index (RSI)
  • LGND 50.22
  • KYN 58.48
  • Support Level
  • LGND $102.79
  • KYN $12.77
  • Resistance Level
  • LGND $112.61
  • KYN $13.18
  • Average True Range (ATR)
  • LGND 4.01
  • KYN 0.28
  • MACD
  • LGND 0.39
  • KYN 0.04
  • Stochastic Oscillator
  • LGND 87.67
  • KYN 85.61

About LGND Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.

About KYN Kayne Anderson Energy Infrastructure Fund Inc.

Kayne Anderson Energy Infrastructure Fund, Inc is a non-diversified, closed-end fund. Its investment objective is to provide a high after-tax total return with an emphasis on making cash distributions to the stockholder. The company seeks to achieve its objectives by investing a majority of its total assets in the securities of Energy Infrastructure companies.

Share on Social Networks: